AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19781665 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive intervention
Number of subjects: 266
Study 19781665 — intervention group
Group type: COMPARATOR
Intervention: Standard care intervention
Number of subjects: 266
Study 17031485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) for diagnosing effusion in GH joints
Number of subjects: 50
Study 17031485 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical assessment of swelling
Number of subjects: 50
Study 17031485 — intervention group
Group type: EXPERIMENTAL
Intervention: Kappa coefficient between clinical assessment and US
Number of subjects: 50
Study 17031485 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (US)
Number of subjects: 50
Study 15821887 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted CMV group
Number of subjects: 81
Study 15821887 — intervention group
Group type: EXPERIMENTAL
Intervention: Reconstituted subjects
Number of subjects: 81
Study 15821887 — intervention group
Group type: COMPARATOR
Intervention: Reconstituted PcP group
Number of subjects: 81
Study 15821887 — intervention group
Group type: COMPARATOR
Intervention: HIV-positive controls
Number of subjects: 81
Study 15821887 — intervention group
Group type: COMPARATOR
Intervention: HIV-negative controls
Number of subjects: 81
Study 12064344 — intervention group
Group type: EXPERIMENTAL
Intervention: Green tea extract (GTE) incorporated into meat patties with a daily intake of 18.6 mg catechins/d
Number of subjects: 16
Study 12064344 — intervention group
Group type: COMPARATOR
Intervention: Control diet low in flavonoids
Number of subjects: 16
Study 10223782 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg policosanol once a day for 12 weeks
Number of subjects: 437
Study 10223782 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg policosanol once a day for the next 12 weeks
Number of subjects: 437
Study 10223782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 437
Study 9048721 — intervention group
Group type: EXPERIMENTAL
Intervention: Gilles de la Tourette syndrome (GTS)
Number of subjects: 150
Study 9048721 — intervention group
Group type: EXPERIMENTAL
Intervention: Obsessive-compulsive disorder (OCD)
Number of subjects: 150
Study 9048721 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 150
Study 9048721 — intervention group
Group type: EXPERIMENTAL
Intervention: OCD with sensory tics
Number of subjects: 150
Study 2037702 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (2, 4, 8 mg)
Number of subjects: 8
Study 2037702 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25, 12.5, 25 mg)
Number of subjects: 8
Study 2037702 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanabenz (8 mg) and Captopril (25 mg) concomitantly
Number of subjects: 8
Study 2037702 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6128860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg/kg)
Number of subjects: 50
Study 6128860 — intervention group
Group type: COMPARATOR
Intervention: Pancuronium
Number of subjects: 50
Study 6128860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium (0.025 mg/kg maintenance doses)
Number of subjects: 50
Study 6128860 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium
Number of subjects: 50
Study 30642311 — intervention group
Group type: EXPERIMENTAL
Intervention: Mothers in Motion intervention
Number of subjects: 612
Study 30642311 — intervention group
Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 612
Study 28656921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine gargle (40 mg in 30 ml normal saline) for 30 sec, five minutes before induction of anaesthesia.
Number of subjects: 150
Study 28656921 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine jelly (2% applied to the ETT cuff) and 30 ml normal saline gargled for 30 sec, five minutes before induction of anaesthesia.
Number of subjects: 150
Study 26467311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D plus calcium supplementation (50,000 IU vitamin D3 every 2 weeks plus 1000 mg day(-1) calcium)
Number of subjects: 60
Study 26467311 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D plus calcium supplementation
Number of subjects: 60
Study 26467311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 23732121 — intervention group
Group type: EXPERIMENTAL
Intervention: Transitional care coaching intervention
Number of subjects: 0
Study 23732121 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 21706212 — intervention group
Group type: EXPERIMENTAL
Intervention: Forming four action plans
Number of subjects: 478
Study 21706212 — intervention group
Group type: EXPERIMENTAL
Intervention: Forming five action plans
Number of subjects: 478
Study 21706212 — intervention group
Group type: COMPARATOR
Intervention: Control group (questionnaires only)
Number of subjects: 478
Study 19940978 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape (TVT) at the time of prolapse repair (group I)
Number of subjects: 181
Study 19940978 — intervention group
Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT) 3 months after prolapse repair (group II)
Number of subjects: 181
Study 19940978 — intervention group
Group type: COMPARATOR
Intervention: Prolapse surgery alone
Number of subjects: 181
Study 17620070 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopic keratoconjunctivitis (AKC)
Number of subjects: 48
Study 17620070 — intervention group
Group type: COMPARATOR
Intervention: Vernal keratoconjunctivitis (VKC)
Number of subjects: 48
Study 17620070 — intervention group
Group type: COMPARATOR
Intervention: Normal control subjects
Number of subjects: 48
Study 16046582 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole (2.5 mg/d) for 28 days
Number of subjects: 20
Study 16046582 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 11934233 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatopharmacokinetic method
Number of subjects: 130
Study 11934233 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical trial method
Number of subjects: 130
Study 10423764 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg orally 45 min before MIBI injection
Number of subjects: 47
Study 10423764 — intervention group
Group type: COMPARATOR
Intervention: No metoclopramide (control)
Number of subjects: 47
Study 7595735 — intervention group
Group type: EXPERIMENTAL
Intervention: FAM2 regimen (fluorouracil [5‐FU], doxorubicin, and mitomycin) administered every 43 days for seven cycles.
Number of subjects: 314
Study 7595735 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery alone)
Number of subjects: 314
Study 2403123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate infusion (1.3%)
Number of subjects: 8
Study 2403123 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride infusion (0.9%)
Number of subjects: 8
Study 2403123 — intervention group
Group type: COMPARATOR
Intervention: Control (no infusion)
Number of subjects: 8
Study 2403123 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate infusion (1.3%)
Number of subjects: 8
Study 6968855 — intervention group
Group type: COMPARATOR
Intervention: Blood cardioplegia (BCP)
Number of subjects: 33
Study 6968855 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid cardioplegia (KCP)
Number of subjects: 33
Study 6968855 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrolyte solution with magnesium (MgKCP)
Number of subjects: 33
Study 31811789 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent acute otitis media (AOM)
Number of subjects: 168
Study 31811789 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent otitis media with effusion (OME)
Number of subjects: 168
Study 31811789 — intervention group
Group type: EXPERIMENTAL
Intervention: Recurrent AOM
Number of subjects: 168
Study 31811789 — intervention group
Group type: EXPERIMENTAL
Intervention: Permanent hearing loss
Number of subjects: 168
Study 31080591 — intervention group
Group type: EXPERIMENTAL
Intervention: Three 'Zesy002' kiwifruit
Number of subjects: 32
Study 31080591 — intervention group
Group type: COMPARATOR
Intervention: Metamucil® (14.75 g, 5 g dietary fibre/d)
Number of subjects: 32
Study 31080591 — intervention group
Group type: COMPARATOR
Intervention: Metamucil®
Number of subjects: 32
Study 25805285 — intervention group
Group type: EXPERIMENTAL
Intervention: Various apparatuses and pressure regimens used to harvest fat tissue
Number of subjects: 15
Study 21833777 — intervention group
Group type: EXPERIMENTAL
Intervention: High-MUFA diet
Number of subjects: 12
Study 21833777 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate/high-fiber/low-glycemic index (CHO/fiber) diet
Number of subjects: 12
Study 21881579 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin treatment (100 mg per day)
Number of subjects: 164
Study 21881579 — intervention group
Group type: COMPARATOR
Intervention: Control group (no aspirin treatment)
Number of subjects: 164
Study 19585102 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (patellar eversion)
Number of subjects: 60
Study 19585102 — intervention group
Group type: COMPARATOR
Intervention: Group B (lateral subluxation)
Number of subjects: 60
Study 17136034 — intervention group
Group type: EXPERIMENTAL
Intervention: High Glycemic Index (HGI) breakfast
Number of subjects: 6
Study 17136034 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate Glycemic Index (MGI) breakfast
Number of subjects: 6
Study 17136034 — intervention group
Group type: COMPARATOR
Intervention: Water (control)
Number of subjects: 6
Study 15531058 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical stimulation of the abductor hallucis muscle (20 min)
Number of subjects: 0
Study 15531058 — intervention group
Group type: COMPARATOR
Intervention: Control (no stimulation)
Number of subjects: 0
Study 11834236 — intervention group
Group type: EXPERIMENTAL
Intervention: Nestorone subdermal implant (NES)
Number of subjects: 200
Study 11834236 — intervention group
Group type: COMPARATOR
Intervention: Copper T intrauterine device (T-Cu)
Number of subjects: 200
Study 9949940 — intervention group
Group type: EXPERIMENTAL
Intervention: etifoxine (150‐200 mg/d)
Number of subjects: 170
Study 9949940 — intervention group
Group type: COMPARATOR
Intervention: buspirone (15‐20 mg/d)
Number of subjects: 170
Study 8310973 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (5-10 mg once daily)
Number of subjects: 0
Study 8310973 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2195596 — intervention group
Group type: EXPERIMENTAL
Intervention: Air insufflation in same-day studies (Group 1)
Number of subjects: 121
Study 2195596 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation in same-day studies (Group 2)
Number of subjects: 121
Study 2195596 — intervention group
Group type: COMPARATOR
Intervention: Separate-day studies (Group 3)
Number of subjects: 121
Study 2195596 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall quality of ACBE studies in all groups
Number of subjects: 121
Study 381073 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-rabies human diploid cell vaccine (HDCV)
Number of subjects: 25
Study 31012044 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D visualization technology
Number of subjects: 88
Study 31012044 — intervention group
Group type: COMPARATOR
Intervention: CT images
Number of subjects: 88
Study 31969307 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rosuvastatin
Number of subjects: 20
Study 29089177 — intervention group
Group type: EXPERIMENTAL
Intervention: High followed by decreasing LTPA among female offspring
Number of subjects: 1408
Study 29089177 — intervention group
Group type: EXPERIMENTAL
Intervention: High then decreasing LTPA among normal weight women
Number of subjects: 1408
Study 29089177 — intervention group
Group type: EXPERIMENTAL
Intervention: LTSB trajectories
Number of subjects: 1408
Study 25569817 — intervention group
Group type: COMPARATOR
Intervention: Alfacalcidol (1 μg/d) alone
Number of subjects: 76
Study 25569817 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (1 μg/d) and raloxifene hydrochloride (60 mg/d)
Number of subjects: 76
Study 22909294 — intervention group
Group type: EXPERIMENTAL
Intervention: Multisystemic therapy (MST)
Number of subjects: 34
Study 22909294 — intervention group
Group type: COMPARATOR
Intervention: Usual care with motivational interviewing (MI)
Number of subjects: 34
Study 21350289 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous mode large spot transpupillary thermotherapy (LS TTT)
Number of subjects: 5
Study 21350289 — intervention group
Group type: COMPARATOR
Intervention: Standard spot sized conventional pulsed mode diode laser
Number of subjects: 5
Study 19361801 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth psychoeducation program
Number of subjects: 184
Study 19361801 — intervention group
Group type: COMPARATOR
Intervention: Routine childbirth education
Number of subjects: 184
Study 17983543 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary rehabilitation program (9-week supervised program including educational sessions, respiratory physiotherapy, and muscle training)
Number of subjects: 38
Study 17983543 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary rehabilitation program
Number of subjects: 38
Study 15298223 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration of sexual violence against intimate partners in the past 10 years
Number of subjects: 1368
Study 15298223 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors associated with sexual violence
Number of subjects: 1368
Study 15298223 — intervention group
Group type: EXPERIMENTAL
Intervention: Types of conflict associated with sexual violence risk
Number of subjects: 1368
Study 11386488 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (7 days treatment)
Number of subjects: 15
Study 9784910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol treatment
Number of subjects: 0
Study 9784910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7888292 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (3.0 to 4.5 micrograms kg‐1)
Number of subjects: 374
Study 7888292 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac (1 mg kg‐1)
Number of subjects: 374
Study 7888292 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (1.5 to 2.0 micrograms kg‐1)
Number of subjects: 374
Study 7888292 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (0.1 to 0.15 mg kg‐1)
Number of subjects: 374
Study 7888292 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalbuphine (0.1 to 0.15 mg kg‐1)
Number of subjects: 374
Study 7888292 — intervention group
Group type: EXPERIMENTAL
Intervention: Pethidine (1.0 to 1.5 mg kg‐1)
Number of subjects: 374
Study 7888292 — intervention group
Group type: COMPARATOR
Intervention: Saline (as control)
Number of subjects: 374
Study 2668252 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin 400 mg bd
Number of subjects: 94
Study 2668252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 94
Study 30608521 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal denervation (RDN)
Number of subjects: 80
Study 30608521 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure
Number of subjects: 80
Study 28655135 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii-Fit
Number of subjects: 30
Study 28655135 — intervention group
Group type: COMPARATOR
Intervention: Walking
Number of subjects: 30
Study 26003919 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure injury prevention care bundle
Number of subjects: 0
Study 26003919 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 23731101 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma clinic intervention providing education, self-monitoring promotion, regular treatment review, and written asthma action plan
Number of subjects: 0
Study 23731101 — intervention group
Group type: COMPARATOR
Intervention: Current practice in asthma management in Australia
Number of subjects: 0
Study 22126164 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed information on morphine (experimental group)
Number of subjects: 100
Study 22126164 — intervention group
Group type: COMPARATOR
Intervention: General information on postoperative acute pain (control group)
Number of subjects: 100
Study 19501762 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive modelling of blue food consumption (Group A)
Number of subjects: 79
Study 19501762 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative modelling of blue food consumption (Group B)
Number of subjects: 79
Study 19501762 — intervention group
Group type: COMPARATOR
Intervention: Alone consumption (Group C)
Number of subjects: 79
Study 19501762 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive modelling (Group A)
Number of subjects: 79
Study 19501762 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative modelling (Group B)
Number of subjects: 79
Study 16532916 — intervention group
Group type: EXPERIMENTAL
Intervention: Atosiban (300 microg/min)
Number of subjects: 16
Study 16532916 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16532916 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin (10 pmol/kg)
Number of subjects: 16
Study 16532916 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemia markers
Number of subjects: 16
Study 15013038 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephonic back-up added to educational strategy
Number of subjects: 128
Study 15013038 — intervention group
Group type: COMPARATOR
Intervention: Educational strategy only (Control)
Number of subjects: 128
Study 10703628 — intervention group
Group type: EXPERIMENTAL
Intervention: Barrier cream
Number of subjects: 25
Study 10703628 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (moisturizing vehicle)
Number of subjects: 25
Study 9109861 — intervention group
Group type: EXPERIMENTAL
Intervention: 4AP SR 17.5 mg bid
Number of subjects: 10
Study 9109861 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 9109861 — intervention group
Group type: EXPERIMENTAL
Intervention: 4AP SR
Number of subjects: 10
Study 8260375 — intervention group
Group type: EXPERIMENTAL
Intervention: Trilostane
Number of subjects: 72
Study 8260375 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminoglutethimide
Number of subjects: 72
Study 8260375 — intervention group
Group type: EXPERIMENTAL
Intervention: Both drugs
Number of subjects: 72
Study 3898949 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 249
Study 3898949 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids
Number of subjects: 249
Study 3898949 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous drip delivery
Number of subjects: 249
Study 3898949 — intervention group
Group type: COMPARATOR
Intervention: Bolus delivery
Number of subjects: 249
Study 31548595 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsule (3000 IU/day)
Number of subjects: 75
Study 31548595 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual spray (3000 IU/day)
Number of subjects: 75
Study 31548595 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 75
Study 30587955 — intervention group
Group type: EXPERIMENTAL
Intervention: O2matic-controlled treatment
Number of subjects: 20
Study 30587955 — intervention group
Group type: COMPARATOR
Intervention: Manual control
Number of subjects: 20
Study 27142676 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week blended care self-management program 'Partner in Balance'
Number of subjects: 80
Study 27142676 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 80
Study 25336514 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care plus early rehabilitation
Number of subjects: 243
Study 25336514 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 243
Study 21399951 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT)
Number of subjects: 10
Study 21399951 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planing (SRP)
Number of subjects: 10
Study 20033825 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic hemostasis with soft coagulation (Group I)
Number of subjects: 96
Study 20033825 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic hemoclipping (Group II)
Number of subjects: 96
Study 20033825 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Group I and Group II)
Number of subjects: 96
Study 18677970 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of triflusal (600 mg)
Number of subjects: 24
Study 18677970 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of triflusal (600 mg)
Number of subjects: 24
Study 18677970 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of HTB
Number of subjects: 24
Study 18677970 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of HTB
Number of subjects: 24
Study 16208839 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg) as augmentation to ongoing antidepressant therapy
Number of subjects: 21
Study 16208839 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (100-400 mg)
Number of subjects: 21
Study 12072038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral soy isoflavone concentrate containing 80 mg of soy isoflavones
Number of subjects: 29
Study 12072038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 10590004 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ketorolac tromethamine 0.5% ophthalmic solution (Acular)
Number of subjects: 200
Study 10590004 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 200
Study 8735993 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal rehearsal
Number of subjects: 64
Study 8735993 — intervention group
Group type: COMPARATOR
Intervention: No rehearsal
Number of subjects: 64
Study 8735993 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal model
Number of subjects: 64
Study 8735993 — intervention group
Group type: COMPARATOR
Intervention: No model
Number of subjects: 64
Study 8735993 — intervention group
Group type: COMPARATOR
Intervention: Model type (for English-speaking children)
Number of subjects: 64
Study 8735993 — intervention group
Group type: COMPARATOR
Intervention: Rehearsal (for LEP children)
Number of subjects: 64